+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan

Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan

International Journal of Clinical Pharmacology and Therapeutics 47(12): 722-725

There is little knowledge regarding the prevalence of mucosal injury (MI) in Japanese patients receiving antiplatelet therapy. This study estimated the prevalence of gastroduodenal MI in asymptomatic Japanese patients taking antiplatelet agents and nonsteroidal anti-inflammatory drugs (NSAIDs). Among patients who underwent an upper gastrointestinal endoscopy at Teikyo University Hospital (Tokyo, Japan), 382 asymptomatic patients taking either low-dose aspirin, ticlopidine, cilostazol, or other NSAIDs and 119 people not taking any of these agents were included. Endoscopic records were evaluated for the presence of MI. Aspirin and NSAIDs users showed a higher prevalence of MI than controls (Aspirin, OR = 2.6 (95% CI = 1.4 - 4.9), NSAIDs, 2.9 (1.4 - 4.4)). Concomitant use of aspirin and NSAIDs increased the prevalence of MI (11.2 (2.8 - 44.8)). Ticlopidine and cilostazol were less likely to cause injury than aspirin and other NSAIDs, the difference remained insignificant due to small sample number (ticlopidine, 0.8 (0.2 - 4.0), cilostazol, 1.3 (0.3 - 4.8)). In asymptomatic Japanese patients receiving low-dose aspirin, the prevalence of the gastroduodenal MI was the same as that in patients taking NSAIDs and higher than that in controls.

(PDF emailed within 1 workday: $29.90)

Accession: 055157944

Download citation: RISBibTeXText

PMID: 19954710

Related references

Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users. Medicine 94(26): E1047, 2015

High prevalence of gastroduodenal mucosal injury in patients taking selective serotonin reuptake inhibitors. Digestive Endoscopy 22(1): 77, 2010

Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. Qjm 104(2): 133-139, 2011

Gastroduodenal mucosal injury in patients on antiplatelet therapy. Thrombosis Research 120(4): 465-469, 2007

Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. Journal of Clinical Biochemistry and Nutrition 47(1): 27-31, 2010

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 51(3): 336-343, 2002

Are Japanese patients more prone to gastro-duodenal mucosal injury and bleeding with the use of antiplatelet agents?. Thrombosis Research 120(4): 463-464, 2007

Screening for Gastric and Small Intestinal Mucosal Injury with Magnetically Controlled Capsule Endoscopy in Asymptomatic Patients Taking Enteric-Coated Aspirin. Gastroenterology Research and Practice 2018: 2524698-2524698, 2018

Short article: Small intestinal mucosal injury in patients taking chemotherapeutic agents for solid cancers. European Journal of Gastroenterology and Hepatology 29(5): 568-571, 2017

Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls. Journal of Clinical Gastroenterology 34(5): 529-532, 2002

Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. Journal of Gastroenterology and Hepatology 29 Suppl 4: 11-15, 2015

Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue. Gastroenterology 92(3): 566-569, 1987

Effects of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy. Journal of Cardiology 54(1): 71-75, 2011

Patients’ awareness of the threat of taking antithrombotic and antiplatelet agents due to cardiological recommendations. Pomeranian Journal of Life Sciences 61(4): 448-453, 2018

No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents. Clinical Gastroenterology and Hepatology 15(1): 46-52, 2016